EXHIBIT 99.1 MANNKIND CORPORATION REPORTS 2024 FIRST QUARTER FINANCIAL RESULTS: PROVIDES CLINICAL DEVELOPMENT UPDATE Conference Call to Begin Today at 5:00 p.m. (ET) • 1Q 2024 Total revenues of $66M; +63$11M; Non-GAAP net income of $15M •$304M of cash and cash equivalents and investments at March 31, 2024 • In early April, repaid Midcap senior-secured debt and Mann Group convertible debt totaling approximately $37M • FDA Fast Track designation and IND clearance receive ...